1237-P: Proteomic Indicators of Metabolic Health in Diabetes and Social Vulnerability

Abstract

Introduction: Understanding the health impacts of socioeconomic deprivation (SED) and its interaction with type 2 diabetes is important for patient care and effective public health initiatives. Large-scale proteomic profiling using aptamer-based technology to measure 7,000 proteins has facilitated the development of blood-based proteomic signatures for 10 cardiometabolic SomaSignal Tests (SST), including a test that predicts the 4-year risk of a cardiovascular event (CV risk). Methods: The cross-sectional PsoBid study recruited participants from socioeconomically deprived and affluent areas of Glasgow, Scotland with similar age ranges and equal proportions of male and female, to identify relevant health disparities. We used regression analyses to estimate the association between SSTs and socioeconomic status (affluent (n = 257, 50.7%), deprived (n = 250, 49.3%)) and prevalent diabetes (n = 27 (5.3%), 7 (2.7%) affluent, 20 (8.0%) SV). Results: Diabetes was associated with SST predicted increased visceral fat, lean body mass, liver fat, body fat percentage, resting energy rate, and CV risk score, and worse proteomic predictors of cardiorespiratory fitness, glucose tolerance, alcohol impact, and kidney health (p<0.05). SED was associated with SST predicted increased visceral adiposity and CV risk score, and decreased cardiorespiratory fitness, glucose tolerance, and kidney health (p<0.05). The association between diabetes and CV risk score was highest among socioeconomically deprived participants (interaction p-value: 0.01). Conclusion: These results demonstrate that participants with diabetes and SED have proteomic phenotypes consistent with decreased cardiometabolic health compared to participants without diabetes or SV and SED is associated with worse predicted cardiovascular risk in patients with diabetes. Proteomics may be useful in identifying and monitoring the health effects of diabetes and SED or the impact of relevant interventions. Disclosure M.Simpson: Employee; SomaLogic Operating CO., Inc. R.Ostroff: Employee; SomaLogic. S.A.Williams: Employee; SomaLogic. N.Sattar: Advisory Panel; Amgen Inc., Boehringer Ingelheim and Eli Lilly Alliance, Novartis, Roche Diagnostics, Consultant; Afimmune Limited, Hanmi Pharm. Co., Ltd., Pfizer Inc., Other Relationship; Abbott, AstraZeneca, Boehringer Ingelheim Pharma GmbH&Co.KG, Eli Lilly and Company, Janssen Pharmaceuticals, Inc., Novo Nordisk, Sanofi, Research Support; AstraZeneca, Boehringer Ingelheim Pharma GmbH&Co.KG, Novartis, Roche Diagnostics.